DaVita Inc. (DVA) Earnings Call Transcript & Summary
April 29, 2021
Earnings Call Speaker Segments
Jim Gustafson
executiveThanks for joining us, and welcome to the conference call for our first quarter. We're grateful that you keep taking an interest in what our company is doing. This is Jim Gustafson speaking — I serve as Vice President of Investor Relations — and with me here today are Javier Rodriguez, who is our CEO, and Joel Ackerman, who is our CFO. Be aware that we might present forward-looking statements on this call, as defined under the federal securities laws. Known and unknown risks and uncertainties apply to each of those statements, and those risks and uncertainties could lead to actual results that differ materially from what the forward-looking statements describe. If you want more information about such risks and uncertainties, please look at the press release for our first quarter earnings as well as the filings we make with the SEC, which include our latest annual report on Form 10-K, our subsequent quarterly report on Form 10-Q, and any filings we later submit to the SEC. The forward-looking statements we make rest on information available to us at present, and we have no intention of updating them, nor do we take on any obligation to do so, unless the law requires it. We'd also like to point out that certain non-GAAP financial measures will be discussed on this call. You can find a reconciliation between those non-GAAP measures and the most comparable GAAP financial measures in our earnings press release, which has been submitted to the SEC and is available on our website. I'll hand the call over to Javier Rodriguez now.
Javier Rodriguez
executiveThanks, Jim, and good afternoon. During the past several months, our fight against the COVID-19 pandemic has seen amazing strides, and with ongoing hope, I'll share a few updates today — beginning with vaccinations, then a recap of Q1 results, after that a refresh on our brighter full-year forecast, and last, a look at what we keep doing around ESG. The first quarter produced plenty of smiles as a kidney care community delivered hundreds of thousands of shots to its patients. We worked hand in hand with the Biden administration, the CDC, and state governments to make it possible for people on dialysis to receive their shots at a place they already trust and find easy to reach. Our thinking was that this would help patients overcome transportation problems and the other barriers that arise when they have to travel to outside facilities. We also believed that once patients received guidance from a caregiver they trust, reluctance would decline. Thanks to the hard work our teams and government partners put in, I'm happy to share that 72% of our patients nationwide had received at least one dose of the vaccine as of yesterday. We also saw an opportunity to advance health equity by administering the COVID vaccine within our own clinics. During the initial weeks of the vaccine rollout, we observed patterns in the broader U.S. population, and our own data showed similar trends: for black and Hispanic individuals, vaccination rates were about 40% lower than for white and Asian Americans. That was unacceptable to us. We sprang into action, mobilizing our care teams—social workers, dietitians, and medical directors included—to engage patients individually and address the usual reasons behind their reluctance. Today, our Hispanic patients are vaccinated at almost the same rate as our white patients, and the disparity for our black patients has been reduced to 10%. Our efforts are ongoing. We remain committed to advancing health equity. Now, turning to the financial outcomes for our first quarter: we turned in a strong Q1, with operating margins recovering to 15.7% during that period, even as we kept guiding the business through ongoing pandemic-related difficulties. As we discussed during our previous call, treatment volumes fell in Q1. Our treatments per day reached their lowest level in mid-February, a figure that included roughly 25,000 mid treatments lost because of the winter storm. From that point forward, our daily treatment trends have shown consistent improvement. Should current patterns hold and no additional waves of infection occur, we think the growth in our patient census from one period to the next, continuing through year-end, may get back to where it stood before COVID — and that assumption is already baked into the guidance ranges we gave you three months ago. We've also shared somewhat more granular information about volume that backs up this outlook. To begin, as noted in our first-quarter update, case counts for COVID and newly identified infections among the patients we serve in dialysis have kept falling. As of this past Friday, active cases among our patients nationwide had dropped roughly 85% compared with the highest prevalence recorded on January 6, 2021. Over the seven days preceding this report, the rate of new cases fell by roughly 91% compared with the week that ended on January 9, 2021. Next, we feel thankful to observe a sharp drop in death rates tied to COVID. As we noted before, the tragic excess deaths linked to COVID came to about 7,000 during 2020; during 2021, the count of deaths among our patients and the count within the broader population both reached their highest point in January. During the first quarter, roughly 3,300 lives were lost in excess because of COVID, and over half of those occurred in January, then fell to about 600 by March; it's still too soon to estimate April, though we anticipate results will be better than March. Turning to the outlook for the full year. Our expectations for core operating performance this year are mostly the same as the guidance we originally gave. Even so, because the odds of some of those downside outcomes have fallen, given the trends I discussed earlier, we're now taking our adjusted earnings per share outlook up to a range of $8.20 to $9 per share, while also raising the range for adjusted operating income to between $1.75 billion and $1.875 billion. If you look at the middle of that revised adjusted operating income range, it works out to about 4% growth over last year. Both of these updated ranges assume the virus doesn't cause any further major disruption. The final thing I want to cover is how committed we remain to environmental, social, and governance issues, which we call ESG. During the last two years or so, ESG has become an increasingly significant subject for discussion and investment among the community. At DaVita, these areas are not new for us. Our convictions are reflected in our stated vision of social responsibility, which contains three parts: looking after our patient, looking after one another, and looking after the world surrounding us, encompassing our communities as well as our environment. DaVita keeps carrying out this vision, and delivering top quality clinical care for our patient sits at the heart of what we do, and since I have already discussed our patient care and our vaccination efforts at length, I want to call attention to a few accomplishments in looking after our teammates and looking after the world surrounding us. In my view, building an environment full of diversity, where each of us feels a sense of belonging, is essential to our culture, to how we relate to one another, and to how we relate to our patients daily. Our dedication to nurturing diversity can be seen across the whole organization. It begins with the Board of Directors, which today consists of nine leaders, 67% of whom are diverse, among them four women and three people of color. That diversity reaches the leaders who oversee core operations in our clinics, 52% of whom are female, while 27% are people of color. We have reached these results by way of thoughtful, deliberate practices aimed at building a diverse pipeline of talent. Back in 2021, we put out an initial report covering diversity and belonging, in which we shared a lot of the varied metrics for our company as part of continuing work to build a diverse organization where each person feels a sense of belonging. Not long ago, we also released our 14th Annual Corporate Social Responsibility report along with our very first ESG report. Those reports set out the headway achieved during 2020 and describe our ambitious ESG targets for 2025, among them cutting carbon emissions by 50%, getting suppliers that account for 70% of emissions to adopt climate change goals, and reaching engagement scores of 84% or better across our teammate population. We feel good about how far we've come so far on diversity and ESG, and as our goals make clear, there's much more we intend to get done. With that, I'll hand things over to Joe.
Joel Ackerman
executiveAppreciate that, Javier. The first quarter got us off to a solid beginning this year, delivering strong financial results. During the quarter, our revenue came in at roughly $2.8 billion, operating income reached $443 million, and earnings per share were $2.09. As Javier mentioned, treatment volume acted as a significant drag, and our non-acquired growth landed at negative 2.2%, versus negative 0.3% in Q4. COVID was the primary difficulty for NAG during Q1. Winter storms, especially Uri, accounted for roughly 30 basis points of that NAG decrease, and treatments per day hit their lowest point in the first quarter. So we anticipate quarter-over-quarter growth beginning in Q2. Our expectation remains that NAG will be negative for the full year, though we do look for NAG to accelerate in 2022 and 2023, since mortality rates could stay below pre-COVID levels for a few years. U.S. dialysis revenue per treatment rose sequentially by nearly $3 this quarter, driven by the Medicare rate increase, greater enrollment in MA plans, a modest gain in commercial mix, and increased volume from our hospital services business. Those gains were partly offset by the seasonal effect of coinsurance and deductible. U.S. dialysis patient care costs fell sequentially by about $6 per treatment, even though we still face elevated costs because of the pandemic, including higher PPE and certain clinical-level expenses tied to ongoing infection control protocol. Our Q1 patient care costs benefited by almost $2 per treatment from our power purchase agreement, a benefit we don't anticipate lasting through the remainder of the year. For the quarter, COVID created a net headwind of roughly $35 million, made up mostly of higher PPE costs and the compounding effect of patient mortality linked to COVID, partly offset by the benefit from the sequestration suspension, along with several other items that largely cancel each other out. For fiscal year 2021, we now project the net negative COVID impact to be about $50 million less than what we guided last quarter. That reflects a lower COVID impact in Q1, the recently passed extension of Medicare sequestration relief through the end of the year, and lower other offsets including T&E in the back half of the year. At the midpoint of our guidance range, that works out to a $150 million negative COVID impact in 2021. Our DSO rose by about seven days in Q1 compared with Q4, mainly because of temporary billing holds tied to the winter storms and shifts in calcimimetics reimbursement. Under certain circumstances, we hold claims to ensure we have complete and accurate charge information for payments. This quarter brought more of those holds, and the last, single largest driver related to winter storm Uri, which hit more than 600 of our centers right in the middle of the quarter. That effectively pushed a significant amount of cash flow out of this quarter and into the next, causing the corresponding DSO increase in the interim. Although timing differences cause cash flow to move around from one quarter to another when it comes to claims, there is no adverse effect and these are amounts we ultimately anticipate collecting; April has already brought a meaningful rise in cash collections, and we anticipate a matching favorable effect on cash flow as well as DSOs across the coming 2 quarters. A few last items. During Q1, 2.9 million shares of our common stock were bought back, and so far in April, we have purchased roughly 1 million more shares. Interest expense came to $67 million for the quarter. We anticipate that quarterly interest expense will rise to roughly $75 million starting in the next quarter, reflecting the $1 billion of notes that were issued in late February. Before we take questions, allow me to offer a few thoughts. During the last 12 months, our teams and our business went through atypical turbulence and difficulties stemming from the pandemic. We made it through this extremely hard stretch thanks to the commitment of our people, our scale, our innovation, and a holistic platform and approach to caring for patients. Looking ahead, our company is in a stronger place. Our bonds with patients have grown deeper, and we are even more certain that our comprehensive kidney care platform is well positioned to provide a best-in-class value proposition for our patients, physicians and hospitals and payer partners. Now, let's begin the Q&A.
Pito Chickering
analystAfternoon, everyone, and I appreciate you fielding my questions. The first one concerns the operating income guidance, which you lifted by 3.5%, equating to roughly $63 million at the midpoint. You mentioned certain pluses and minuses — sequestration and/or the COVID effect, plus reduced costs during the latter half of the year. Could you help us measure what actually drove those?
Joel Ackerman
executiveOf course. Hi, Pito, Joel speaking. I'd frame it around three items, really. We outperformed in this quarter, so clearly that's a benefit for the entire year. Sequestration stood out as the primary factor, accounting for approximately $50 million. Then, as we look at the second half, we've reduced certain COVID offsets we had anticipated from G&A and T&E. With conditions improving somewhat, we didn't anticipate the same level of offset during Q3 and Q4. Combine all of that, and that's your final result.
Pito Chickering
analystAll right. And after that, our treatment growth was down 1.3% from the prior quarter and 2.2% compared with the same period a year earlier. I know that many treatments were missed because of host relations tied to the storms. Those losses are being made up for by your acute business and, clearly, by the mortality issue. That said, could you possibly provide monthly treatment figures for the quarter and for April? Or at least give us some sense of how quickly things are recovering and how you intend to bring patient census back to pre-COVID levels by the time the year ends.
Joel Ackerman
executiveYes. Pito, thanks for asking that. We won't provide monthly numbers, but let me try to offer some help. The low point came in February. That was mostly due to the mortality issue, but also because of Uri, the storm, which caused roughly 25,000 treatments to be missed; in March we saw improvement both as the mortality issue eased and as things came back after the storm, and then April was somewhat better still. I think it's a bit soon to put a number on it and try to use that to establish a trend line. Figures like these can move around somewhat. So that's the situation.
Pito Chickering
analystAnd then for the final question, revenue per treatment came in quite robust, given everything you mentioned. So I have two brief things to ask. First, what level of co-pay pressure showed up during the first quarter? Then what would be a sensible figure to assume for revenue per treatment in 2Q? And when you think about the coming couple of years, is there any reason a 2% growth rate in revenue per treatment would not be the correct thing to assume?
Joel Ackerman
executiveYes. So there are a few points I want to call out regarding Q1 RPT. When it comes to putting a number on the co-insurance and deductible, that falls in the neighborhood of $5 to $6 per treatment. So that amount would be added to whatever you anticipate for Q2. We additionally saw a step-up in Q1 versus Q4 because of calcimimetics. As a reminder, calcimimetics OI for 2021 is going to be comparable to 2020, though the seasonal shape is going to look quite different. So from that, we gained $2 — roughly $2 of RPT in Q1 compared with Q4. Regarding the outlook for what RPT is going to be, as you may recall, we no longer provide guidance on RPT. As for what counts as a sensible figure, is 2% sensible? I would not call it unreasonable, though it could be somewhat toward the upper end of the range I tend to think about, but we will obviously have more to share about 2022 RPT later this year.
Pito Chickering
analystExcellent. Many thanks.
Joel Ackerman
executiveOperator, my apologies. Pito, let me just add something there — regarding what I said, you would clearly need to make an adjustment for sequestration, and presumably that disappears somewhere between 2022 and 2021, and that figure would be substantial.
Pito Chickering
analystSure, absolutely. It's really just about setting aside sequestration, to focus on the pluses and minuses in total market demand. As for the move toward MA, was 2% a fair way to think about it?
Joel Ackerman
executivePrecisely.
Kevin Fischbeck
analystGreat. Thanks. Perhaps we can remain on RPT briefly. When you enumerated the factors affecting RPT this quarter, would it be reasonable to conclude they were given by significance, with the rate update being the largest?
Joel Ackerman
executiveI would say four items exist, and all of them are approximately equal in magnitude: the Medicare rate update, calcimimetics, the mix changes — commercial mix change and then MA. Each is roughly comparable in size.
Kevin Fischbeck
analystAll right, that’s useful; and then, I suppose, as we consider the volume gains you anticipate later in the year, how should we frame that in terms of mix? Would those added volumes come disproportionately from commercial? And would that carry any consequences for margins or profits?
Joel Ackerman
executiveYes; I would say it’s likely the mix skews more toward Medicare than commercial. Keep in mind, the mortality tied to COVID fell heavily on older individuals, as one would anticipate, and our senior members are largely Medicare. So as the COVID impact continues to unwind across the next X number of years, we believe that would push our commercial mix somewhat lower over time. Regarding what it means for margin, there is something that offsets this, given that these additional patients will occupy capacity that’s currently idle, which tends to lift margins. Which of those two opposing dynamics ends up dominating is still uncertain, and it’s a hard figure to forecast since it hinges on many of the same foundational assumptions.
Kevin Fischbeck
analystAll right, that clears things up. If it wasn’t completely obvious, I wanted to understand what you meant regarding the bridge to the guidance. You mentioned he removed some of the COVID offsets — is the basic idea that you had planned for conditions to worsen, with cost reductions ready to go, and now that results are improving, there’s less pressure to implement those cuts as aggressively?
Joel Ackerman
executiveNo, our T&E has declined. It has been lower from the start of COVID, since teammates are traveling less, and our model assumed that would persist until the year was over. Now we believe, for instance, that T&E during Q3 and Q4 might come back nearer to pre-COVID levels. So that offset — the gain we received from reduced T&E — will likely be smaller than what we had expected.
Kevin Fischbeck
analystAll right, that's useful. And I suppose for my final question, could you provide an update regarding your contracting outlook for Medicare Advantage? Is there any sizable book of business scheduled for renewal in the coming year? And what's the status when it comes to rates and discussions about shifting toward more value based models?
Javier Rodriguez
executiveYes, Kevin, Javier here. How are you doing? I appreciate the question. Let me begin by noting that we're not seeing any surge or shift in the number of renewals or anything of that nature — it's following its usual cycle. Our discussions remain very, very closely aligned, focused on making certain we deliver additional value to patients and assist throughout the care continuum. So, and given that we're engaging in more complex contracts, rather than fee-for-service, that means more time is required. So when it comes to that, there isn't really anything to discuss, since the outlook remains essentially the same, and it's factored into our guidance.
Kevin Fischbeck
analystAll right, thanks.
Javier Rodriguez
executiveThank you.
Justin Lake
analystThank you. Good afternoon. A handful of questions for you. To start, regarding the revised guidance, it sounds like you mentioned conditions improving somewhat where COVID is concerned, and I believe you cited $50 million once everything is combined, and that's essentially what we raised or what you took the guy by? So does that suggest the first quarter came in ahead of my model and, I think, ahead of consensus? So does that mean the quarter was actually roughly consistent with your expectations? Or was Q1 significantly stronger from an OI standpoint?
Joel Ackerman
executiveYes, I would say, Justin, that Q1 fell inside the range we had anticipated, I would describe it as somewhat on the favorable side, but it's early in the year to begin adjusting our full year guidance and our full year forecast. So in spite of what I would call a strong quarter, we decided to hold things steady.
Justin Lake
analystAll right. Then regarding that $150 million figure — Joel, if I heard you right, that was the net impact from COVID headwinds?
Joel Ackerman
executiveThat's right, across the full year.
Justin Lake
analystOver the entire year, got it. Alright, though it seems like multiple pieces are involved there, correct? When I consider it, COVID-related expenses exist as one element, plus there's the adverse effect on therapies, and then you have the upside from sequestration, which from what you're saying was included; and on top of that, certain cost offsets come into play. So I'm simply attempting to figure out, could you possibly assist us in breaking down those 4 categories?
Joel Ackerman
executiveYeah. You've captured it accurately; and my view is that in the end, this is a rather straightforward computation. You consider the additional costs tied to PPE, and sequestration approximately balances that out. After that, all remaining items net to zero, and what you're left with is essentially the adverse effect of mortality, which falls within that $150 million range. Thus, numerous shifting parts are present, yet on balance, they largely offset one another, leaving the mortality impact.
Justin Lake
analystAll right. Now, when you consider how mortality affects things — clearly, as you mentioned, we likely hit a low point during Q1, and improvement is anticipated as the year goes on. So I'm just attempting to work out how quickly that plays out, that $150 million figure, correct? Since the exit rates will matter a lot once we're past Q4, when thinking about what it means for the following year. So could you assist us in reasoning through that, regarding where you believe that effect lands this quarter? And where do you believe that effect will stand, roughly, in Q4?
Joel Ackerman
executiveYeah. This subject becomes quite technical quite fast. Still, allow me to attempt to assist you. The way I'd approach it, to make it simpler, is to begin with our standard NAG. Should you wish to pick a figure, look back to before COVID and choose a value around the low 2%s — 2.2%, roughly that. And you truly observe it being affected by whatever ongoing excess mortality exists; though once more, we believe that is dropping swiftly — you'll likely notice a bit during Q2, yet it falls fast, again, presuming COVID unfolds as we anticipate while it fades away. Still, clearly, circumstances might differ. So begin with NAG, incorporate excess mortality, then make an adjustment for whatever might prove difficult regarding the pipeline, should you wish to suppose there are any CKDs affecting it. We lack data about that. Yet when we examine what we observe concerning new agonists, we notice no effect there — we notice no effect from that at present — but you would need to factor that in. After that, we foresee a tailwind emerging as patients who would otherwise have passed away during the coming quarter or two died because of COVID. And measuring that is tough. So that's the way I'd build the model. If you prefer something fairly basic — and I understand I'm giving you many figures along with a complex narrative. I believe…
Justin Lake
analystI'm really hoping we can get the ideal Joel here.
Joel Ackerman
executiveYou put back the benefit that came from reduced mortality after COVID. That gives you the starting point for projecting what NAG will look like ahead.
Justin Lake
analystFine, I’m not clever enough to work that one out. We can discuss it when we’re not on this call. Only one more thing. Could you share how the commercial mix shifted between what you saw during the fourth quarter and what you’re seeing now in the first quarter?
Joel Ackerman
executiveIt rose by a modest degree — not by much — yet it did increase somewhat.
Justin Lake
analystOkay. Appreciate it, everyone.
Pito Chickering
analystHi, thanks for fielding my follow-up. A few fast items. Looking at buybacks, the last 2 years have been quite enjoyable, so I'm wondering what management views as the appropriate amount of leverage for the company right now, and where the remaining capacity ought to go — more repurchases — is it near 3.5? I'd like some sense of how we should weigh leverage against repurchasing stock.
Joel Ackerman
executiveSure. Well, our stance here has been fairly steady, I'd say. Nothing much is different. Our target is that 3 to 3.5 times range, and currently we sit at 3.39. During the quarter we completed a bond issuance worth $1 billion. For the balance of the year, cash flow should be fairly robust. Q1 cash flow, as you observed, came in soft. We expect to recover that across the year, and there's no basis to expect our thinking and strategy regarding leverage and buybacks to shift in the near term.
Pito Chickering
analystThe second item is a faster one — for Medicare Advantage penetration, what share did you have this year compared with last year?
Joel Ackerman
executiveIn our previous disclosure, we stated that our expectation matches what we described: mid-to-high 30%, while markets sit at approximately 43%. As a result, we remain a bit under the broader market, still within that mid-to-high 30s band.
Pito Chickering
analystAll right, so in this quarter, what share of patients got their treatment at home, and are you seeing that speed up in the post-COVID setting?
Joel Ackerman
executiveThat share is roughly flat, since NAG has been going down, yet that piece of our business did grow — PD specifically, which was up about 4%. On the home hemodialysis side, the HH portion declined, but taken together, that area of our operations keeps expanding; we believe physicians and patients alike want greater flexibility and freedom. We're also innovating and building plenty of technology so patients feel at ease, more confident, and more convenient while staying linked to our care site. So we anticipate these modalities will keep growing.
Pito Chickering
analystOkay, great. Thanks so much guys.
Joel Ackerman
executiveThank you.
Javier Rodriguez
executiveAll right, so ideally that brief indicates it came across clearly. I'll offer a few final remarks. For me personally, and deep within my heart, plus for a great many of our caregivers, the first quarter of 2021 will forever stand out and bring a great deal of satisfaction because we vaccinated literally 10s of 1000s of patients — which, in numerous cases, without exaggeration or dramatizing it, was literally life sustaining. Next, the financial results for the quarter are fairly uncomplicated, and assuming the virus shifts, we start moving along a course back toward our historical normalization. And finally, our teams kept up their steadfast dedication to caring and innovating so that our patients' lives improve. We appreciate your interest in DaVita. And we can't wait to speak with you before long. Stay safe.
Operator
operatorThanks. That brings today’s call to a close. We appreciate everyone taking part. At this point, you’re free to hang up.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.